Nuvectis Pharma, Inc. Operating Income Loss

Quick Answer

Nuvectis Pharma, Inc. reported Operating Income Loss of -$27.57 million for the year ending 2025.

  • Nuvectis Pharma, Inc. showed a decrease of -38.9% in Operating Income Loss from 2024 to 2025.
  • This data is from Nuvectis Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), Nuvectis Pharma, Inc.'s Operating Income Loss has declined by 113.9%.
  • Historical annual values: Fiscal year 2025: -$27.57 million | Fiscal year 2024: -$19.85 million | Fiscal year 2023: -$22.90 million | Fiscal year 2022: -$19.23 million | Fiscal year 2021: -$12.89 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: